AtheroGenics Company Description
Drug company AtheroGenics develops drug candidates for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. Its lead candidate, AGI-1067, is an oral drug intended to improve blood sugar levels. Development of the therapeutic compound is ongoing despite disappointing results from a major AGI-1067 clinical trial, which led to the termination of a licensing agreement with AstraZeneca and an organizational restructuring that cut AtheroGenics' workforce in half in 2007. The company's alliance with Astellas Pharma on a second anti-inflammatory candidate, organ transplant drug AGI-1096, also ended. In 2008 the company filed for Chapter 11 bankruptcy protection.
View the Comprehensive Company Description for AtheroGenics
The Company Description provides a historical perspective of AtheroGenics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of AtheroGenics's evolution in the marketplace.
